The METHYLOMIC project has been kicked off!

The efficiency and cost-effectiveness will also be assessed in great detail, and experts will guide regulatory approval to ensure delivery of the first epigenetic kit personalised treatment of CD.

The efficiency and cost-effectiveness will also be assessed in great detail, and experts will guide regulatory approval to ensure delivery of the first epigenetic kit personalised treatment of CD.
February 3, 2023

The project will build on multiple previous cohort studies that confirmed epigenetic biomarkers (specificaly DNA methylation) as the most stringent predictor of response to biological therapy, zooming in on CD. The project aims to bring personalised treatment selection in CD and other IMID to clinical practice and will look into research for further validation studies to develop a marketable rapid, targeted methylation assay that will then be validated in a unique prospective randomised clinical trial for CD.

Asphalion will be in charge of the Regulatory pathway throughout the project and during the kick-off presented the tasks that shall be performing and the regulatory challenges that lie ahead:

  • Regulatory Roadmap
  • Regulatory Plans (Design and Development, Risk Management, Usability and Software Validation)
  • Quality Control support
  • Contact with regulatory bodies and Notified Bodies
  • Support during IVD Performance Studies and Performance Study submission

 

The consortium comprises eighteen participants consisting of clinical, epigenetic, and DNA diagnostics experts, patient organisations, and companies across nine countries to ensure effective communication and commitment to help ease the challenges of patients with Crohn’s disease.

For further information, you can contact us at: info@asphalion.com

Search News & Events

  • Filter by category

Share

Related news and events

In2Sight | 4th annual meeting 3RS congress

At ASPHALION, we are part of the IN2SIGHT consortium, an EU-funded project, and we are delighted to be currently participating in the 4th annual meeting

Course | Regulatory aspects of vaccine development

TRANSVAC2 supported innovation for both prophylactic and therapeutic vaccine development by providing high-quality technical services across four different service platforms: Technology (for process development and GMP production), Immunocorrelates & Systems Biology, Animal models, and support for Clinical Trials. TRANSVAC also offered training courses to provide fundamental and advanced knowledge on a wide-range of vaccine development-related topics.

ASPHALION HIGHLIGHTS Q2 2023

A lot of things have happened during these past three months. We received an award from AEFI as most engaged Company with its employees’ traning;

For further information

If you are interested in our services, or wish to get in touch for a general enquiry, please contact us for more information.

Fill the form and we will contact you as soon as possible.

You can also follow us on:

Schedule a Free Meeting

Schedule here a free 30-minutes meeting with one of our consultants and tell us about your project, challenges or doubts. 

We will be happy to assist you!

Schedule a meeting